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Abstract
Background: The subject of death and bereavement in the context of randomised controlled trials in neonatal or 
paediatric intensive care is under-researched. The objectives of this phase of the Bereavement and RAndomised 
ControlLEd Trials (BRACELET) Study were to determine trial activity in UK neonatal and paediatric intensive care (2002-
06); numbers of deaths before hospital discharge; and variation in mortality across intensive care units and trials and to 
determine whether bereavement support policies were available within trials. These are essential prerequisites to 
considering the implications of future policies and practice subsequent to bereavement following a child's enrolment 
in a trial.
Methods: The units survey involved neonatal units providing level 2 or 3 care, and paediatric units providing level II 
care or above; the trials survey involved trials where allocation was randomized and interventions were delivered to 
intensive care patients, or to parents but designed to affect patient outcomes.
Results: Information was available from 191/220 (87%) neonatal units (149 level 2 or 3 care); and 28/32 (88%) 
paediatric units. 90/177 (51%) eligible responding units participated in one or more trial (76 neonatal, 14 paediatric) 
and 54 neonatal units and 6 paediatric units witnessed at least one death. 50 trials were identified (36 neonatal, 14 
paediatric). 3,137 babies were enrolled in neonatal trials, 210 children in paediatric trials. Deaths ranged 0-278 (median 
[IQR interquartile range] 2 [1, 14.5]) per neonatal trial, 0-4 (median [IQR] 1 [0, 2.5]) per paediatric trial. 534 (16%) 
participants died post-enrolment: 522 (17%) in neonatal trials, 12 (6%) in paediatric trials. Trial participants ranged 1-236 
(median [IQR] 21.5 [8, 39.8]) per neonatal unit, 1-53 (median [IQR] 11.5 [2.3, 33.8]) per paediatric unit. Deaths ranged 0-
37 (median [IQR] 3.5 [0.3, 8.8]) per neonatal unit, 0-7 (median [IQR] 0.5 [0, 1.8]) per paediatric unit. Three trials had a 
formal policy for responding to bereavement.
Conclusions: A substantial number of deaths after trial enrolment were identified, distributed over many trials and 
units. Few trial teams had responses to bereavement in place. Those with the largest numbers of deaths might be best 
placed to collaborate in developing and assessing responses to bereavement.
Background
The current emphasis on the need for good evidence to
guide care [1,2], and the establishment of the UK Medi-
cines for Children Research Network (MCRN) to encour-
age and facilitate paediatric research, suggest that
increasing numbers of children will be enrolled into ran-
domised controlled trials. This includes extremely sick
children in neonatal and paediatric intensive care units,
of whom a proportion will die before discharge home.
The subject of death and bereavement in the context of
trials is, however, under-researched.
It is not known how many participants are enrolled in
this setting, or how many survive or die. The parents of
those who go on to die subsequent to trial enrolment may
have a range of information and support needs and pref-
erences but these have not yet been adequately described
and explored. We do not know whether bereaved parents
might wish to have further contact with a trial, and what
services, if any, they might wish to access; we do not
know what approaches clinicians and trial teams might
feel able to offer.
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and trials is to ascertain the magnitude and distribution
of post-trial mortality. This study therefore aimed to
determine:
1. trial activity in UK neonatal and paediatric units;
2. the number and proportion of deaths among babies 
and children participating in trials in intensive care;
3. variation in mortality across units, and across trials
4. whether any provision is made for bereavement 
within trials
Methods
Although new trials are increasingly being registered,
especially those involving new medical products, there is
no single repository of trials through which all trials con-
ducted in the UK over specified time periods and particu-
lar specialties can be identified. The Bereavement and
RAndomised ControlLEd Trials (BRACELET) Study
therefore required two linked surveys to achieve its
objectives; the first survey involved neonatal and paediat-
ric units to identify trials conducted in the UK in 2002-
2006; the second survey involved trials to collate data on
deaths across trials and across their collaborating neona-
tal and paediatric units (Figure 1).
Unit survey
The unit survey aimed to identify all trials open to
recruitment in the UK from 1 January 2002 to 31 Decem-
ber 2006. Data were requested from all neonatal units
providing care designated as Level 2 (high dependency
and some short-term intensive care) or Level 3 (whole
range of medical care but not necessarily specialist ser-
vices such as surgery) [3], and all paediatric units with a
paediatric intensivist in post which provide at least Level
II intensive care (1:1 nurse:child ratio providing care for
those requiring continuous nursing supervision, usually
intubated and ventilated, or unstable non-intubated or
recently extubated) [4].
Two hundred and twenty neonatal unitsand 32 paediat-
ric units were identified through a process of cross-
checking multiple sources [3-9]. Units were contacted by
post but questionnaires were also made available on the
BRACELET website http://www.bracelet-study.org.uk.
One hundred and forty nine neonatal units reported their
designated level of care as Level 2 or 3 and were eligible to
participate in the study. Representatives at these 149 neo-
natal units, and at the 32 Level III paediatric units [7,9]
were asked to complete a questionnaire in April 2007.
This asked respondents to list all trials open to recruit-
ment in their unit in 2002-2006. The clinical lead for each
unit was asked to permit the trial coordinating team for
each trial to which they had recruited to release that
unit's recruitment and mortality data to the BRACELET
Study. Two reminders were sent via email or mail. Nurse
Practitioners from MCRN made additional follow up
contact where appropriate. Opportunistic and direct con-
tact between study members and units also served as
reminders. Data collection was concluded in May 2008.
Trials survey
The unit survey generated a list of trials which was sup-
plemented by searches of specialised websites [8-10].
Many of the trials were also identified through other
sources such as the UK Dept Health National Research
Register https://portal.nihr.ac.uk/Pages/
NRRArchive.aspx, PubMed http://
www.ncbi.nlm.nih.gov/pubmed, PICS website http://
www.ukpics.org, and the European Society of Paediatric
and Neonatal Intensive Care website http://www.esp-
nic.de.
Trials were eligible for the survey if: allocation was ran-
domised; enrolment took place during the five year study
period; parental informed consent was required; and the
intervention was delivered to babies or children within
ICUs or delivered by, or under the auspices of, a neona-
tologist or paediatric intensivist leading to ICU admission
for ongoing care, or the intervention was delivered to par-
ents but designed to affect outcomes for babies or chil-
dren.
For each eligible trial, the chief investigator, trial man-
ager or other appropriate contact was asked to complete
an emailed questionnaire. Questionnaires were also made
available on the BRACELET website http://www.brace-
let-study.org.uk/index.php?page=previous-research---
phase-1 were followed up by telephone, direct contact
and the assistance of MRCN, if necessary. The informa-
tion received was supplemented by data from published
papers, relevant websites and personal communication.
Three types of data were generated, for the five year study
period only: general data about trials (outcome measures,
participating units, numbers enrolled); overall mortality
data (UK mortality per trial before discharge from hospi-
tal) and unit-specific mortality data (deaths per unit per
trial before discharge from hospital). Chief investigators,
trial managers or other appropriate contacts were alsoFigure 1 Structure of BRACELET Study Surveys.
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Page 3 of 9asked to provide copies of the trial protocol and parent
information leaflets for their trial.
Analysis
Descriptive data are presented as proportions and ranges,
as appropriate. Analysis used the statistical package Stata
10 (StataCorp, College Station, Texas, USA). Variations in
the denominators for some of the numbers reported in
the results reflect different response rates for the unit sur-
vey and the trials survey, and incomplete release of mor-
tality data by some units and some trials.
Ethics
Ethics committee approval was not required for this
phase of the BRACELET Study.
Results
Response rates
Unit survey
Questionnaires were sent to 220 neonatal units; 191
(86.8%) responded, of which 149 were eligible units (82
providing Level 2 care and 67 Level 3). Questionnaires
were also completed by 28 (87.5%) of the 32 Level II pae-
diatric units surveyed.
Trials survey
The unit survey and associated searches identified 50 tri-
als (36 neonatal and 14 paediatric trials). Some general
data were obtained for 43 trials (32 neonatal, 11 paediat-
ric). Overall UK mortality data were released for 37 trials
(28 neonatal, 9 paediatric). Unit-specific mortality data
were released for 33 trials (24 neonatal, 9 paediatric) for
those ICUs which had permitted release of their data to
the study in the unit survey.
Survey findings
The unit survey indicated that overall half of the ICUs
enrolled one or more participants in one or more trials
during the five year study period (76/149 neonatal units,
14/28 paediatric units) (Table 1).
A minority of the responding Level 2 neonatal units (N
= 27, 32.9%) and the majority of the responding Level 3
neonatal units contributed to a trial (N = 49 (73.1%). Nine
(13.4%) of the Level 3 neonatal units ran their own single
centre trials but none of the Level 2 neonatal units did so.
Five of the 14 responding paediatric units (17.9%) ran sin-
gle centre trials.
General data
Of the 76 neonatal units which enrolled to a trial, 72 pro-
vided details of the number of babies enrolled. A total of
3117 babies were enrolled by these neonatal units into the
29 neonatal trials for which some enrolment data for the
five year study period were available. The number of
babies enrolled per neonatal unit ranged 1-236 (median
[IQR] 21.5 [8, 39.8]). An additional 20 babies were
recruited into two multicentre neonatal trials by two pae-
diatric units, bringing the total enrolled in neonatal trials
to 3137 babies. Of these 480 (15.3%) were recruited into
single centre trials and 2657 (84.7%) into multicentre tri-
als (UK and international) (Table 2).
Of the 14 paediatric units that enrolled into a paediatric
trial, 11 provided details of the number enrolled. A total
of 210 children were enrolled by these paediatric units
into 9 paediatric trials for which some enrolment data for
the five year study period were available. The number of
children enrolled per paediatric unit into paediatric trials
ranged 1-53 (median [IQR] 7 [2], 34). Of these 94 (44.8%)
were enrolled into single centre trials and 116 (55.2%) to
multicentre trials (all of which were international) (Table
2).
Overall mortality data
Overall mortality data were available for 28 neonatal and
9 paediatric trials (Table 3). In total, 534/3288 (16.2%)
children died following enrolment in these 37 trials.
The 28 neonatal trials enrolled 3,088 babies, of whom
522 (16.9%) died. The number of deaths per neonatal trial
ranged 0-278 (median [IQR] 2 [1, 14.5]) (Figure 2). Of the
28 neonatal trials, 24 had at least one death. The highest
mortality rate amongst these trials was 29% (80 deaths).
Most reported small numbers of deaths (only 8 trials
reported >10). The majority of deaths, 429/522 (82.2%),
occurred in four trials, three of which were multicentre
(N = 278 + 80 + 43 and one single centre (N = 28). Single
centre trials reported fewer deaths and a lower death rate
(47/480 9.8%) than multicentre trials (475/2608 18.2%).
In the nine paediatric trials for which mortality data
were available, 12 (6.0%) out of 200 children died follow-
ing enrolment into a trial. Six of the 9 trials had a least
one death with the number of deaths ranging 0-4. Very
few deaths occurred in single centre paediatric trials (2/
94 2.1%) compared to those in the neonatal single centre
Table 1: NICU and PICU participation in RCTs (based on 
respondents to unit surveys)
No. RCTs NICUs PICUs
Total, n = 149
n (%)
n = 28
n (%)
0 73 (49.0) 14 (50.0)
1 31 (20.8) 8 (28.6)
2 19 (12.8) 3 (10.7)
3 13 (8.7) 1 (3.6)
≥4 13 (8.7)* 2 (7.1)**
≥ 1 RCT 76 (51.0) 14 (50.0)
* 10 × 4, one each 5, 6, and 7
**One 4 and one 7
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10/106 (9.4%).
Unit-specific mortality data
Data on 434 deaths were released by 24 neonatal trials for
72 neonatal units with the permission of the neonatal
units in question. The number of deaths per neonatal unit
ranged 0-37 (median [IQR] 3.5 [0.3, 8.8]) (Figure 3).
Whilst 54 neonatal units saw at least one death, more
than half (42/72 58.3%) saw fewer than five deaths over
this five year period (Table 4). Five Level 3 neonatal units
had larger numbers (N = 37, 29, 26, 22 and 20) and 30.9%
of all deaths recorded by the units occurred in these five
neonatal units. In around half of the units, the proportion
Table 2: Babies and children enrolled 2002-2006 by type of trial and by enrolling unit (neonatal or paediatric)
No. enrolled from
neonatal units
No. enrolled from paediatric
units
Total no. enrolled
NEONATAL TRIALS
No. of trials 29 2 29*
No. of units 36 2 38
No. of babies enrolled 3117 20 3137
No. of babies enrolled per recruiting unit; Median 
[IQR]
1-236
21.5 [8, 39.8]
4 and 16** 1-236
20 [7.8, 39.3]
No. of babies enrolled per trial;
Median [IQR]
1-1322
40 [13.5, 104]
4 and16** 5-1326
40 [14.5, 104]
PAEDIATRIC TRIALS
No. of trials 9 9
No. of units 11 11
No. of children enrolled 210 210
No. of children enrolled per recruiting unit;
Median [IQR]
1-53
11.5 [2.3, 33.8]
1-53
11.5 [2.3, 33.8]
No. of children enrolled per trial;
Median [IQR]
2-53
10.5 [6, 39.3]
2-53
10.5 [6, 39.3]
ALL NEONATAL/PAEDIATRIC TRIALS
No. of babies/children enrolled 3117 230 3347
No. of trials 29 11 38*
*includes two neonatal trials which recruited from both neonatal and paediatric units
** no median and IQR as only two trials
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or more (Table 5).
Nine paediatric trials released unit specific mortality
data for 14 paediatric units. The number of deaths per
paediatric unit ranged 0-7(median [IQR] 0.5 [0, 1.8]),
with 6 paediatric units witnessing at least one death
(Table 4). In all these units, the proportion of children
who died following trial enrolment was under 20% (Table
5).
Trials survey - Practices in relation to bereavement care
Of the 50 RCTs, investigators for just over half (n = 27)
provided a copy of the full trial protocol. None of the pro-
tocols documented a policy relating to the care of parents
bereaved following enrolment of their child into the RCT.
Parent information leaflets were provided for 29 of the
50 trials. Two NIC trials (one multicentre and one UK-led
international trial) provided a leaflet specifically for
bereaved parents, expressing condolences, thanking them
for their contribution and offering information about the
trial. Details of support organisations were also given in
the leaflets.
In one single-centre NIC trial the investigator reported
a different approach. Three deaths occurred following
enrolment into this trial and the investigator sent a per-
sonalised letter to each set of parents to thank them for
allowing their child to participate and to offer contact
should they wish to discuss the trial or the continued use
for their child's data in the trial.
Discussion
The BRACELET Study is the first to investigate ran-
domised controlled trial activity in UK neonatal units and
paediatric units, to report the numbers of babies and chil-
dren enrolled into trials, and to determine the extent and
distribution of mortality involved. An important strength
of this study is the high response rates achieved. Several
evidence-based strategies were used to maximise
responses [11]. We are confident that all units were iden-
tified, and the comprehensive process of searching rele-
vant research databases and websites as well as surveying
these units is likely to have identified most of the trials
recruiting in the UK. The establishment of mandatory
trial registration will facilitate this process for future
studies. There are, however, clear limitations to the study
which relate to its narrow focus on mortality figures; in
this regard the data raise rather than answer questions
about bereavement in this context.
The study shows that in a five year period, over 3000
babies and children were enrolled into paediatric and
neonatal intensive care trials and 16% died, predomi-
nantly in the neonatal context. With over 500 deaths
reported we suggest that a substantial number of
bereaved parents, clinicians and trialists have encoun-
tered deaths among trial participants. We would also sug-
gest that this is an underestimate as the BRACELET
study focused only on deaths up to discharge from hospi-
tal; post-discharge deaths were not included. Other
adverse outcomes for parents and families, such as dis-
ability and loss of quality of life in surviving babies are
also important but were beyond the remit of the study.
As further trials are initiated and accrue more partici-
pants, the population of parents bereaved after agreeing
to enroll their child in a trial will accumulate; it is already
Table 3: Hospital survivors and non-survivors overall by type of 
RCT - UK totals 2002-2006 (overall mortality data)
NEONATAL TRIALS (n = 28)
No. of babies enrolled 3088
No. of babies outcome unknown 2
No. of babies survived 2564
No. of babies died 522
Mortality rate % (based on known outcomes) 16.9
PAEDIATRIC TRIALS (n = 9)
No. of children enrolled 200
No. of children outcome unknown 0
No. of children survived 188
No. of children died 12
Mortality rate % (based on known outcomes) 6.0
NEONATAL and PAEDIATRIC TRIALS (n = 37)
No. of babies/children enrolled 3288
No. of babies/children outcome unknown 2
No. of babies/children survived 2752
No. of babies/children died 534
Mortality rate % (based on known outcomes) 16.2
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how to respond to this population are complex questions.
Provision for bereavement is often made within clinical
centres but this body of parents, with potentially diverse
experiences and needs, is largely scattered across a num-
ber of recruiting clinical centres; most deaths occurred as
relatively isolated cases and the majority of centres wit-
nessed small numbers of deaths per year. In the paediatric
context where few deaths occurred, only one ICU
reported more than one death. This is likely to make it
difficult for many of the clinical centres to develop, assess
and sustain specialised responses to post-trial bereave-
ment themselves.
The patterns of mortality revealed by the BRACELET
Study also suggest, however, that there were pockets of
neonatal units and neonatal trials with substantial num-
bers of deaths. Five particularly research active Level 3
neonatal units saw 20 or more deaths each in the study
period, and together they saw over a quarter of all
reported deaths. In general, large ICUs draw upon well
developed bereavement services [12], and research-active
centres such as these may be appropriate candidates to
develop and assess dedicated trial-related bereavement
practices.
The vast majority of deaths represented in the BRACE-
LET Study, also occurred in only four trials. In trials
where a substantial number of deaths is anticipated, it
may be possible to develop and assess trial-related
bereavement practices.
What form those practices might take is unclear. They
may range from development of formal practices and
Figure 2 Variation in numbers of deaths across neonatal trials.
 
Figure 3 Variation in numbers of deaths across neonatal units.
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parents the opportunity to discuss a trial if they so wish.
Parents have not yet been asked about any support and
information needs that they might have. Their prefer-
ences are likely to be varied and may include the wish for
no further contact. It is however possible that some
options that parents might appreciate, for instance access
to specialised forms of support, may be beyond the
capacity and expertise of current routine bereavement
services, even in the larger centres, and may be difficult
for trial teams to implement.
The BRACELET Study showed that three trials had
already developed a response to bereavement such as pre-
paring a bereavement leaflet for use in clinical centres or
sending condolence letters directly to parents (for an
example leaflet see http://www.npeu.ox.ac.uk/down-
Table 4: Numbers of deaths in NICUs and PICUs following enrolment into a trial 2002-2006 (unit-specific mortality data)
No. of deaths NEONATAL INTENSIVE CARE UNITS PAEDIATRIC INTENSIVE CARE UNITS
No. (%) of Units (n = 72) No. of Units (n = 12*)
None 18 (25) 6
1-4 24 (33) 5
5-9 13 (18) 1
10-14 8 (11) 0
15-19 4 (6) 0
≥20 5 (7) 0
Total no. of deaths in these units 434 14
No. (%) of units seeing at least 
one death
54 (75) 6 (43)
Table 5: Proportion of deaths in NICUs and PICUs following enrolment into a trial 2002-2006 (unit-specific mortality data)
Proportion of deaths NEONATAL INTENSIVE CARE UNITS PAEDIATRIC INTENSIVE CARE UNITS
No. (%) of Units (n = 72) No. of Units (n = 12*)
0 18 (25) 6
0-0.1 10 (14) 3
0.1-0.2 14 (19) 3
0.2-0.3 16 (22)
0.3-0.4 7 (10)
0.4-0.5 5 (7)
≥0.5 2 (3)
* No mortality information was available for two of the 14 Units
Snowdon et al. Trials 2010, 11:65
http://www.trialsjournal.com/content/11/1/65
Page 8 of 9loads/nest/NEST-Bereavement-Leaflet.pdf). Personal
communications have revealed that some trials offer
bereaved parents the option of receiving trial newsletters
and results; some make a considered choice not to con-
tact bereaved parents at all subsequent to a death.
To our knowledge, none of these policies have been
subject to empirical evaluation, although descriptive
accounts such as Strohm's report of a trial-related web-
based message board for all parents of babies recruited to
a trial, including those who are bereaved [13], are helpful
additions to the literature. Further reflection would be of
value to future trials where deaths are likely.
The BRACELET Study has demonstrated that bereave-
ment occurs in relation to trials of any size and type and
with a range of clinical foci. The four trials which
reported the majority of deaths in the five year period
assessed very different interventions, from routine care
practices to potentially life-saving technologies. They
involved very different populations and were conducted
in single centre, multicentre and international contexts.
This suggests that bereavement in a trial context may be
an issue of broad relevance in specialties such as intensive
care, and that it could be particularly appropriate for
large trials, or trials focusing on high risk situations, to
plan for and assess their approach to bereavement with
substantial research populations.
Trials are complex, highly collaborative endeavors
between recruiting clinical centres and trial teams,
groups which may feel a shared interest in and responsi-
bility for parents bereaved in trials. Their collaboration
might be exploited to good effect if experts within these
fields take collective responsibility for the potential needs
of the population identified here. If those trials and clini-
cal centres with the greatest experience of post-trial
bereavement develop effective approaches to care for and
support bereaved parents, other smaller trials and centres
may draw upon their recommendations and follow their
lead. Even in the paediatric context where deaths
occurred infrequently, individual trials may still involve
severely compromised populations and so find that post-
trial bereavement care is a salient issue.
It is, however, important that recommendations in this
novel area should from an early stage be based on sound
empirical evidence which draws upon views of all rele-
vant parties with their potentially different perspectives
and insights. Clinical teams often recruit to a number of
trials concurrently and see bereaved parents in a variety
of circumstances; they may be best placed to consider the
broad range of bereavement-related issues that might
occur in clinical contexts. Trial teams by comparison
consider parents in the relatively more uniform circum-
stances set by the eligibility criteria for their particular
trial; they may be best placed to consider bereavement
practices which are tailored to fit the population and cir-
cumstances of a given trial. Research in this area is sensi-
tive but it is essential that bereaved parents should also be
consulted. Studies have demonstrated that bereavement-
related research is feasible [14-20], and suggest that
bereaved parents might be willing and helpful partici-
pants on this challenging and sensitive subject.
The task ahead is for those with relevant insight and
expertise, to collaborate to find a range of approaches
which are sensitive to the variety of parents seen by clini-
cians and applicable and adaptable to the specific circum-
stances addressed in individual trials. As a first step in
this process the BRACELET Study includes a second
qualitative component which aims to explore death,
dying and bereavement in the context of neonatal RCTs
from the perspectives of trial team members, clinicians
and bereaved parents.
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